Dr. Kazandjian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1120 NW 14th St.
Room 828
Miami, FL 33129Phone+1 305-243-4860- Is this information wrong?
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 2003 - 2006
Boston University School of MedicineClass of 2003
Certifications & Licensure
VA State Medical License 2004 - 2026
FL State Medical License 2020 - 2025- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Clinical Trials
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry Start of enrollment: 2022 Jul 01
Roles: Contact
- Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2022 Sep 27
Roles: Contact
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Start of enrollment: 2023 Mar 26
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Genomic Classification and Individualized Prognosis in Multiple Myeloma.Durante, M. A., Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, Alexandra M Poos, Andriy Derkach, Kylee Maclachlan, Michael Durante, Benjamin Diamond, Marios P...> ;Journal of Clinical Oncology. 2024 Apr 10
- Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer Therapies.Coffey, D. G., Andrew Kowalski, Jill Lykon, Benjamin Diamond, David G Coffey, Marcella Kaddoura, Francesco Maura, James E Hoffman, Dickran Kazandjian, Ola Landgren> ;Blood Cancer Discovery. 2024 Mar 1
- 2 citationsGenomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.Francesco Maura, Eileen M Boyle, David Coffey, Kylee Maclachlan, Dylan Gagler, Benjamin Diamond, Hussein Ghamlouch, Patrick Blaney, Bachisio Ziccheddu, Anthony Cirrinc...> ;Nature Cancer. 2023 Dec 1
- Join now to see all
Abstracts/Posters
- Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple MyelomaDickran Kazandjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to DisagreeDickran Kazandjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Sylvester Pursues Landmark Research Presented at International Hematology ConferenceJanuary 30th, 2023- Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall SurvivalJanuary 4th, 2022
- Bispecific Antibody Shows Promise in R/R Multiple MyelomaAugust 20th, 2021
- Join now to see all
Hospital Affiliations
UMHC - Sylvester ComprehensiveMiami, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
